Among survivors of non-small cell lung cancer, nearly 8% developed non-lung secondary cancers over about 6 years, and this ...

Topline data were announced from a phase 3 trial evaluating ceralasertib plus Imfinzi in patients with locally advanced or metastatic NSCLC.

Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...

The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for reflexive ...

Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and ...

Oncology announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated ...

Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

How Does Libtayo Work for Non-Small-Cell Lung Cancer (NSCLC)? Libtayo is a specific kind of medicine called immunotherapy. Immunotherapies work by helping your body’s own immune system work to fight ...

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...